

# July 2019 Drug Utilization Review Board Meeting Summary

Information posted August 30, 2019

The Texas Drug Utilization Review (DUR) Board met July 26, 2019, to make recommendations for Medicaid clinical prior authorizations and the Preferred drug List (PDL). A [summary of this meeting](#) is now available at the Texas Vendor Drug Program (VDP) website.

## Clinical Prior Authorization Reminders

- Clinical prior authorizations for [traditional Medicaid](#) and [Medicaid managed care organizations](#) (MCOs) may differ. The [Pharmacy Clinical Prior Authorization Assistance Chart](#) identifies each MCO's prior authorizations and how they relate to the prior authorizations for traditional Medicaid.
- Each MCO [pharmacy website](#) must include a list of the clinical prior authorizations that are active for that MCO.

## Preferred Drug List Reminders

- All PDL recommendations are pending until the Texas Health and Human Services Commission (HHSC) executive commissioner releases a final decision. HHSC-approved decisions from the July and October 2019 board meetings will be incorporated into the PDL published in January 2020.
- Prescribing providers must use the Medicaid formulary and the PDL.
- MCOs must adhere to the Medicaid formulary and the PDL and should check the drugs' formulary status before checking the preferred status.

## About the Texas DUR Board

The next board meeting is scheduled for Friday, October 25, 2019. Board members meet quarterly in Austin to recommend outpatient prescription drugs in the Medicaid program. The schedule of upcoming meetings, instructions on how to submit written materials to the board, and directions about publicly testifying before the board are available on the [VDP website](#).